Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance, Compliance, & Regulatory Information

Guidance, Compliance, & Regulatory Information

                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Good Review Practices | GRPsGuidance, Compliance, & Regulatory Information Good Review Practices | GRPs
  
  	
    Share
    Post
    Linkedin

    Email
    Print**Good Review Practices (GRPs)**

A Good Review Practice, or GRP, is a “documented best practice” within CDER that discusses any aspect related to the process, format, content and/or management of a product review.  GRPs are:

developed over time as superior practices based on experience, and provide consistency to the overall review process of new products
	developed to improve the quality of reviews and review management. GRPs improve efficiency, clarity, and transparency of the review process and review management
	adopted by review staff as standard processes through supervisor mentoring, implementation teams and formal training when necessaryAs GRPs develop, review staff will adopt them into their daily review activities. Since GRPs can change and evolve frequently as a result of new science, statutes, regulations, guidances, and accumulated experience, the policies will be updated regularly. Titles of GRP MaPP and Guidance documents within CDER are listed below.  The most up to date documents can be found on the FDA Guidance Documents and CDER Manual of Policies & Procedures (Mapp) search pages.

Review staff are expected to follow GRPs and may depart from them only with appropriate justification and supervisory concurrence.

The GRP initiative is a true collaborative effort between many Offices within CDER.

General / Review Management

Good Review Practices (MaPP)
	Good Review Management Principles and Practices for PDUFA Products (Guidance)
	Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics (MaPP)
	Good Review Practice: Review of Marketing Applications for Breakthrough Therapy-Designated Drugs and Biologics That Are Receiving an Expedited Review (MaPP)
	Best Practices for Communication Between IND Sponsors and FDA During Drug Development  (Guidance)
	NDAs/BLAs: Using the 21st Century Review Process Desk Reference Guide (MaPP)Biometrics

Good Review Practice: Statistical Review Template (MaPP)Clinical

Good Review Practice:  Clinical Consultative Review of Drugs Regulated Within OND (MaPP)
	Good Review Practice: Clinical Review Template (MaPP) (See Attachment B)
	Good Review Practice: Good Review Management Principles and Practices for Effective IND  Development and Review (MaPP)
	Good Review Practice: Clinical Review of Investigational New Drug Applications (MaPP) (Review Document)
	Good Review Practice: Refuse to File (MaPP)
	Premarket Risk Assessment  (Guidance)
	Evaluating the Risks of Drug Exposure in Human Pregnancies (Guidance)Clinical Pharmacology

Good Review Practices: Clinical Pharmacology Review of New Molecular Entity (NME) New Drug Applications (NDAs) and Original Biologics License Applications (BLAs) (MaPP)
	Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications (Guidance)
	Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns (Guidance)Nonprescription Products

Good Review Practice: OND Review Management of INDs and NDAs for Nonprescription Drug Products (MaPP)Safety

Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (Guidance)
	Drug Safety Information - FDA's Communication to the Public (Guidance)
	Risk Management Plan Activities in OND ( the Office of New Drugs) and ODS ( the Office of Drug Safety) (MaPP)Chemistry, Manufacturing, and Controls

Pharmacology/Toxicology

Back to Top

                                                                                  Content current as of:
      02/20/2018Guidance, Compliance, & Regulatory Information

          
                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop